GRI
GRI Standard 2021 Index
Statement of Use | The 2025-26 Hanmi Pharmaceutical ESG Report is prepared in compliance with the GRI Standard 2021 Index and records sustainability management performance from January 1 to December 31, 2025. Additionally, information that could significantly influence stakeholder decisions includes activities up to April 2026 and additional data from previous years. |
|---|---|
GRI 1 used | GRI 1 : Foundation 2021 |
Applicable GRI | As of May 2026, when Hanmi Pharmaceutical publishes its report, there are no applicable GRI Sector Standards published through GRI. Hanmi Pharmaceutical identifies and reports material issues from the perspective of the future of the domestic pharmaceutical industry and risks and opportunities that may arise across its business operations. |
General Disclosures
Category | Indicators | Description | Contents | Remarks |
|---|---|---|---|---|
GRI 2: | 2-1 | Organizational Information | ||
2-2 | Entities included in the organization's sustainability report | |||
2-3 | Reporting period, frequency, and contact point | |||
2-4 | Restatements of Information | - | Annotation for each piece of information where applicable | |
2-5 | External Assurance | |||
2-6 | Activities, value chain, and other business relationships | |||
2-7 | Employees | |||
2-8 | Workers who are not employees | |||
2-9 | Governance structure and composition | |||
2-10 | Recommendation and Selection of the Highest Governance Body | |||
2-11 | Chair of the Highest Governance Body | |||
2-12 | Role of the Highest Governance Body Regarding Impact Management | |||
2-13 | Delegation of Responsibility for Impact Management | |||
2-14 | Role of the Highest Governance Body Regarding Sustainability Reporting | |||
2-15 | Conflict of Interest | |||
2-16 | Reporting of Material Matters | |||
2-17 | Overall Knowledge of the Highest Governance Body | |||
2-18 | Performance Evaluation of the Highest Governance Body | |||
2-19 | Remuneration Policy | |||
2-20 | Remuneration Decision-Making Process | |||
2-21 | Annual Total Compensation Ratio | - | ||
2-22 | Statement Regarding Sustainable Development Strategy | |||
2-23 | Policy Commitment | |||
2-24 | Internalization of Policy Commitments | Compliance Education / Safety and Health Education | ||
2-25 | Process for Addressing Negative Impacts | GMP Compliance / Reporting and Handling of Violations | ||
2-26 | Mechanism for seeking advice and raising concerns | Reporting and Handling of Violations | ||
2-27 | Compliance with Laws and Regulations | 2025 Administrative Sanctions / | ||
2-28 | Membership Associations | |||
2-29 | Stakeholder Engagement Approach | |||
2-30 | Collective Bargaining Agreements |
Material Topic
Category | Indicators | Description | Contents | Remarks |
|---|---|---|---|---|
GRI 3: | 3-1 | Process for Determining Material Topics | ||
3-2 | List of Material Topics |
Category | Indicators | Description | Contents | Remarks |
|---|---|---|---|---|
Material Topic 1. Ensuring Pharmaceutical Product Safety | ||||
GRI 3: | 3-3 | Management of Material Topics | ||
GRI 416: | 416-1 | Assessment of Health and Safety Impacts of Product and Service Categories | ||
416-2 | Cases of Violations of Laws and Regulations Regarding Health and Safety Impacts of Products and Services | |||
Material Topic 2. Expansion of Ethical and Compliance Management | ||||
GRI 3: | 3-3 | Management of Material Topics | ||
GRI 205: | 205-1 | Assessment of corruption risks in operations | ||
205-2 | Communication and training on anti-corruption policies | |||
205-3 | Confirmed incidents of corruption and actions taken | |||
GRI 206: | 206-1 | Legal actions regarding anti-competitive behavior, monopolies, and other unfair trade practices | ||
Material Issue 3. Strengthening workplace safety and health | ||||
GRI 3: | 3-3 | Management of Material Topics | ||
GRI 403: | 403-1 | Workplace occupational health and safety management system | ||
403-2 | Hazard identification, risk assessment, and incident investigation | Identification of risks and opportunities | ||
403-3 | Workplace health services | |||
403-4 | Worker participation, consultation, and communication on workplace safety&health | |||
403-5 | Worker occupational health and safety training | |||
403-6 | Worker health promotion | |||
403-7 | Prevention and mitigation of occupational health and safety impacts directly influenced by the nature of operations | Occupational Health and Safety Management System / Occupational Health and Safety Training | ||
403-8 | Workers covered by occupational health and safety management systems | |||
403-9 | Work-related injuries | |||
403-10 | Work-related diseases | |||
Material Issue 4. Responsible Supply Chain Management | ||||
GRI 3: | 3-3 | Management of Material Topics | ||
GRI 414: | 414-2 | Negative social impacts in the supply chain and actions taken | ||
Material Issue 5. Information Security, including Personal Data Protection | ||||
GRI 3: | 3-3 | Management of Material Topics | ||
GRI 418: Customer Privacy 2016 | 418-1 | Number of substantiated complaints regarding breaches of customer privacy and loss of customer data | ||
Topic Standards
Category | Indicators | Description | Contents | Remarks |
|---|---|---|---|---|
Biodiversity | ||||
GRI 101: | 101-1 | Policies for halting and reversing biodiversity loss | Company's commitments regarding biodiversity and no deforestation | |
101-2 | Biodiversity impact management | |||
101-3 | Access and benefit-sharing | |||
101-8 | Ecosystem services | |||
Economy | ||||
GRI 201: | 201-1 | Direct Economic Value Generated and Distributed | ||
201-2 | Financial Implications and Other Risks and Opportunities due to Climate Change | |||
201-3 | Defined Benefit Plan Obligations of the Organization | - | 2025 Audit Report | |
GRI 202: | 202-2 | Proportion of Senior Management Hired from the Local Community at Significant Locations of Operation and Definition | ||
GRI 203: | 203-1 | Infrastructure Investments and Services Supported | ||
203-2 | Significant Indirect Economic Impacts | Financial Soundness through Improved New Drugs | ||
Environment | ||||
GRI 302: | 302-1 | Energy Consumption within the Organization | ||
302-3 | Energy Intensity | |||
302-4 | Reduction in Energy Consumption | |||
GRI 303: | 303-2 | Management of impacts related to water discharge | ||
303-3 | Water sources | |||
303-4 | Water discharge volume | |||
303-5 | Water usage volume | |||
GRI 305: | 305-1 | Direct Greenhouse Gas Emissions (Scope 1) | ||
305-2 | Indirect Greenhouse Gas Emissions (Scope 2) | |||
305-3 | Other Indirect Greenhouse Gas Emissions (Scope 3) | |||
305-4 | Greenhouse Gas (GHG) Emissions Intensity | |||
305-5 | Greenhouse Gas (GHG) Emissions Reduction | |||
305-7 | Nitrogen Oxides (NOx), Sulfur Oxides (SOx) and Other Major Air Emissions | |||
GRI 306: | 306-1 | Waste Generation and Major Waste-Related Impacts | ||
306-2 | Management of Major Waste-Related Impacts | |||
306-3 | Waste Generation | |||
306-4 | Waste Recycling | |||
Social | ||||
GRI 401: | 401-1 | New Hires and Turnover | ||
401-2 | Benefits for full-time employees not offered to non-regular employees | |||
401-3 | Parental leave | |||
GRI 404: | 404-1 | Average training hours per employee | ||
404-2 | Employee competency development and transition support programs | |||
404-3 | Percentage of employees who received regular performance and career development reviews | |||
GRI 405: | 405-1 | Diversity of governance bodies and employees | Employee Diversity / Composition of Board and Executive Management | |
405-2 | Ratio of basic salary and remuneration for women to men | |||
GRI 408: | 408-1 | Operations and suppliers at high risk for incidents of child labor | ||
GRI 409: | 409-1 | Operations and suppliers at high risk for incidents of forced labor | ||
GRI 415: | 415-1 | Political contributions | - | In accordance with Article 31 of the Political Funds Act, the Company, as a corporate entity, is prohibited from making any form of political contributions (financial or in-kind). |
GRI 417: | 417-1 | Requirements for product and service information and labeling | Accurate Product Information and labeling materials Management | |
417-2 | Cases of non-compliance with regulations concerning information and labeling for products and services | |||
417-3 | Cases of legal and regulatory violations related to marketing communications | - | No violations |
SASB
Biotechnology and Pharmaceuticals
Topic | Code | Category | Content | Contents |
|---|---|---|---|---|
Safety of | HC-BP-210a.1 | Indicators | Discussion on management procedures to ensure quality and patient safety in clinical trials across various global regions | - |
Response | Hanmi Pharmaceutical conducts audits through its QA team before and during clinical trials, manages and supervises the progress of clinical trials through regular meetings, and performs monitoring progress and data quality checks through Accompany visits. | |||
Drug | HC-BP-250a.1 | Indicators | List of products enumerated in the U.S. Food and Drug Administration (FDA)'s MedWatch Safety Alerts for Human Medical Products database | |
Response | Hanmi Pharmaceutical's products are not included in the FDA's MedWatch list. To provide high-quality pharmaceuticals to customers, we manage products by establishing a safety management system throughout the entire lifecycle of pharmaceuticals, implementing product anti-counterfeiting systems, labeling systems, and regularly responding to audits from global regulatory agencies (such as FDA, PMDA, MHLW). | |||
HC-BP-250a.2 | Indicators | Number of deaths related to products reported in the FDA Adverse Event Reporting System (FAERS) | - | |
Response | Adverse events related to Hanmi Pharmaceutical's products are collected, and the number of reported products and deaths are managed in the Ministry of Food and Drug Safety's (MFDS) database, but these are not disclosed in FAERS. | |||
HC-BP-250a.3 | Indicators | Number of announced recalls and total recalled quantity | ||
Response | Number of recalls: 1 / Total volume: 6.41 tons | |||
HC-BP-250a.4 | Indicators | Total quantity of products approved for recall, reuse, or disposal | ||
Response | The total amount of pharmaceutical products recalled and disposed of in 2025 was 6.41 tons. | |||
HC-BP-250a.5 | Indicators | Number of FDA sanction measures taken by type in response to violations of FDA current Good Manufacturing Practices (cGMP) | - | |
Response | Number of FDA sanctions: 0 | |||
Counterfeit | HC-BP-260a.1 | Indicators | Description of methods and technologies used to maintain product traceability throughout the supply chain and prevent counterfeiting | |
Response | Hanmi Pharmaceutical uses Radio Frequency Identification (RFID) tagging to prevent product counterfeiting and trace product history. | |||
HC-BP-260a.2 | Indicators | Discussion of procedures for warning consumers and business partners about potential or known risks associated with counterfeit products | ||
Response | To ensure accurate product information, Hanmi Pharmaceutical manages its labeling to convey all essential information without omission. For some high-risk products, the company submits a risk management plan to the Ministry of Food and Drug Safety and strictly manages labeling violations. | |||
HC-BP-260a.3 | Indicators | Number of actions that led to crackdown, seizure, arrest, and/or criminal charges related to counterfeit products | ||
Response | Number of detected cases: 0 | |||
Ethical | HC-BP-270a.1 | Indicators | Total amount of monetary losses resulting from legal proceedings related to false marketing claims | |
Response | Hanmi Pharmaceutical incurred no monetary losses in 2025 due to legal proceedings related to false marketing. | |||
HC-BP-270a.2 | Indicators | Description of the code of ethics that controls the promotion of off-label use of products | ||
Response | Hanmi Pharmaceutical reviews the approval status and clarity of labeling and phrases used in marketing, etc., through its 'Pharmaceutical Promotional Material Review Regulations'. | |||
Employees | HC-BP-330a.1 | Indicators | Discussion on efforts to recruit talent and retain scientists and R&D personnel | - |
Response | Hanmi Pharmaceutical is doing its best to secure global R&D talent, including by participating in a large-scale talent exchange roadshow hosted by the Korea Trade-Investment Promotion Agency (KOTRA) titled 'The Invitation: Korea Awaits Your Brilliance). | |||
HC-BP-330a.2 | Indicators | (1) Voluntary and (2) involuntary turnover rates for (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all other employees | ||
Response | This information is recorded in this report's ESG Factbook - Human-Centered Management Performance - Employee Tenure and Leave of Absence. | |||
Supply Chain | HC-BP-430a.1 | Indicators | The percentage of (1) company facilities and (2) Tier I supplier facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or an equivalent third-party audit program, for the integrity of the supply chain and raw materials. | |
Response | Although we do not participate in the Rx-360 International Pharmaceutical Supply Chain Consortium, we have established and operated regulations and guidelines for sustainable supply chain management since 2023. In 2025, we conducted ESG diagnostic assessments for 109 partners and in-depth assessments for 36 partners. Hanmi Pharmaceutical plans to continuously expand the scope of due diligence and advance its supply chain due diligence system in the future. | |||
Business | HC-BP-510a.1 | Indicators | Total monetary losses resulting from legal proceedings related to corruption or bribery | - |
Response | No monetary losses related to corruption or bribery occurred in 2025. | |||
HC-BP-510a.2 | Indicators | Description of the code of ethics governing interactions with healthcare professionals | - | |
Response | Hanmi Pharmaceutical adheres to legal compliance by observing the scope of permissible economic benefits, etc., as stipulated by Article 44 of the Enforcement Rules of the Pharmaceutical Affairs Act of domestic law. |
TCFD
Topic | Measurement Indicators | Contents |
|---|---|---|
Corporate | Board oversight of climate-related risks and opportunities | |
Management's role in assessing and managing climate-related risks and opportunities | ||
Strategy | Climate-related risks and opportunities identified by the organization across the short, medium, and long term | |
The impact of climate-related risks and opportunities on the organization's business, strategy, and financial planning | ||
Resilience of the organization's strategy, taking into account various climate-related scenarios, including those consistent with a 2°C or lower scenario | ||
Risk | The organization's processes for identifying and assessing climate-related risks | |
The organization's processes for managing climate-related risks | ||
How processes for identifying, assessing, and managing climate-related risks are integrated into the organization's overall risk management | ||
Metrics and | The metrics used by the organization to assess climate-related risks and opportunities in line with its strategy and risk management processes | |
Scope 1, Scope 2, and, if appropriate, Scope 3 greenhouse gas (GHG) emissions and related risks | ||
The targets used by the organization to manage climate-related risks, opportunities, and performance against objectives |